Healthcare provider profile · identity verified

Shehzad Kamran, MD

Psychiatry · WEST DES MOINES, IA · NPI 1942247739

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Trazodone Hcl	Trazodone Hcl	628	103
Lorazepam	Lorazepam	606	85
Quetiapine Fumarate	Quetiapine Fumarate	604	75
Lamotrigine	Lamotrigine	594	90
Clonazepam	Clonazepam	544	80
Buspirone Hcl	Buspirone Hcl	461	72
Bupropion Xl	Bupropion Hcl	384	61
Duloxetine Hcl	Duloxetine Hcl	381	63
Fluoxetine Hcl	Fluoxetine Hcl	329	53
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	315	50
Venlafaxine Hcl Er	Venlafaxine Hcl	306	47
Alprazolam	Alprazolam	298	42
Trintellix	Vortioxetine Hydrobromide	272	35
Sertraline Hcl	Sertraline Hcl	258	38
Aripiprazole	Aripiprazole	233	41
Clozapine	Clozapine	214	15
Olanzapine	Olanzapine	208	27
Mirtazapine	Mirtazapine	205	37
Risperidone	Risperidone	204	30
Escitalopram Oxalate	Escitalopram Oxalate	196	38
Benztropine Mesylate	Benztropine Mesylate	161	30
Prazosin Hcl	Prazosin Hcl	153	18
Zolpidem Tartrate	Zolpidem Tartrate	148	30
Hydroxyzine Pamoate	Hydroxyzine Pamoate	143	17
Ziprasidone Hcl	Ziprasidone Hcl	132	15
Hydroxyzine Hcl	Hydroxyzine Hcl	120	23
Eszopiclone	Eszopiclone	102	17
Divalproex Sodium Er	Divalproex Sodium	90	14
Lurasidone Hcl	Lurasidone Hcl	80	suppressed
Gabapentin	Gabapentin	76	suppressed
Topiramate	Topiramate	73	suppressed
Vraylar	Cariprazine Hcl	73	suppressed
Citalopram Hbr	Citalopram Hydrobromide	72	20
Haloperidol	Haloperidol	66	11
Temazepam	Temazepam	64	suppressed
Rexulti	Brexpiprazole	56	suppressed
Propranolol Hcl	Propranolol Hcl	52	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	50	suppressed
Divalproex Sodium	Divalproex Sodium	49	suppressed
Donepezil Hcl	Donepezil Hcl	48	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	47	suppressed
Lithium Carbonate	Lithium Carbonate	47	suppressed
Zaleplon	Zaleplon	46	13
Fluphenazine Hcl	Fluphenazine Hcl	45	suppressed
Caplyta	Lumateperone Tosylate	44	suppressed
Dexmethylphenidate Hcl Er	Dexmethylphenidate Hcl	41	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	41	suppressed
Paliperidone Er	Paliperidone	40	suppressed
Paroxetine Hcl	Paroxetine Hcl	37	suppressed
Metformin Hcl Er	Metformin Hcl	36	suppressed
Vilazodone Hcl	Vilazodone Hcl	33	suppressed
Diazepam	Diazepam	32	suppressed
Modafinil	Modafinil	32	suppressed
Austedo	Deutetrabenazine	31	suppressed
Lithium Carbonate Er	Lithium Carbonate	31	suppressed
Oxcarbazepine	Oxcarbazepine	31	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	30	suppressed
Auvelity	Dextromethorphan Hbr/Bupropion	28	suppressed
Doxepin Hcl	Doxepin Hcl	28	suppressed
Memantine Hcl	Memantine Hcl	28	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	26	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	24	suppressed
Methylphenidate Er	Methylphenidate Hcl	24	suppressed
Bupropion Hcl	Bupropion Hcl	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Atropine Sulfate	Atropine Sulfate	19	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Ingrezza	Valbenazine Tosylate	19	suppressed
Naltrexone Hcl	Naltrexone Hcl	19	suppressed
Invega Sustenna	Paliperidone Palmitate	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Carbamazepine	Carbamazepine	15	suppressed
Lybalvi	Olanzapine/Samidorphan Malate	15	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	14	suppressed
Fetzima	Levomilnacipran Hcl	13	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	13	suppressed
Carbamazepine Er	Carbamazepine	12	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Acamprosate Calcium	Acamprosate Calcium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error